• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在转移性前列腺癌男性患者中分离和增殖循环肿瘤细胞的策略

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer.

作者信息

Theil Gerit, Bialek Joanna, Weiß Christine, Lindner Felix, Fornara Paolo

机构信息

Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic and Outpatient Clinic for Urology, 06120 Halle (Saale), Germany.

出版信息

Diagnostics (Basel). 2022 Feb 15;12(2):497. doi: 10.3390/diagnostics12020497.

DOI:10.3390/diagnostics12020497
PMID:35204587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8870963/
Abstract

Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer (PCa)-specific CTC identification and analysis is crucial. We used the CellCollector EpCAM-functionalized system (CC-EpCAM) and evaluated and developed a PCa-functionalized version (CC-PCa); we then compared CTC isolation techniques that exploit the physical and biological properties of CTCs. We established two cohorts of metastatic PCa patients (mPCa; 15 in cohort 1 and 10 in cohort 2). CTC cultivation experiments were conducted with two capturing methods (Ficoll and ScreenCell). The most sensitive detection rates and highest CTC counts were reached with the CC-PCa and ScreenCell system. Patients with ≥5 CTCs isolated with CC-EpCAM had an overall survival (OS) of 0.93 years, and patients with ≥5 CTCs isolated with CC-PCa had an OS of 1.5 years in cohort 1. Nevertheless, we observed the highest sensitivity and specificity for 24-month survival by the Ficoll with CD45 depletion and ScreenCell system with May-Grunwald Giemsa (MGG) staining. The EpCAM molecule is an essential factor related to OS for CTC isolation based on biological properties in mPCa patients. The best-suited CTC capture system is not limited to one characteristic of cells but adapted to downstream analysis.

摘要

选择一种适合的方法来分离/鉴定循环肿瘤细胞(CTC)具有挑战性。评估用于前列腺癌(PCa)特异性CTC鉴定和分析的敏感且特异的标志物至关重要。我们使用了细胞收集器EpCAM功能化系统(CC-EpCAM),并评估和开发了一种PCa功能化版本(CC-PCa);然后我们比较了利用CTC物理和生物学特性的CTC分离技术。我们建立了两组转移性PCa患者队列(mPCa;队列1中有15例,队列2中有10例)。使用两种捕获方法(Ficoll和ScreenCell)进行了CTC培养实验。CC-PCa和ScreenCell系统达到了最敏感的检测率和最高的CTC计数。在队列1中,用CC-EpCAM分离出≥5个CTC的患者总生存期(OS)为0.93年,用CC-PCa分离出≥5个CTC的患者OS为1.5年。然而,我们观察到,通过Ficoll去除CD45和使用May-Grunwald Giemsa(MGG)染色的ScreenCell系统,对24个月生存期具有最高的敏感性和特异性。在mPCa患者中,基于生物学特性,EpCAM分子是与CTC分离的OS相关的一个重要因素。最适合的CTC捕获系统不限于细胞的一个特征,而是要适应下游分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/add5264c1945/diagnostics-12-00497-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/17dbb649dcbe/diagnostics-12-00497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/87d318141672/diagnostics-12-00497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/d8aaa1b26c82/diagnostics-12-00497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/73d144d18af6/diagnostics-12-00497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/ad7f5b7cd958/diagnostics-12-00497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/167ff9db84fa/diagnostics-12-00497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/57687813659f/diagnostics-12-00497-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/add5264c1945/diagnostics-12-00497-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/17dbb649dcbe/diagnostics-12-00497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/87d318141672/diagnostics-12-00497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/d8aaa1b26c82/diagnostics-12-00497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/73d144d18af6/diagnostics-12-00497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/ad7f5b7cd958/diagnostics-12-00497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/167ff9db84fa/diagnostics-12-00497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/57687813659f/diagnostics-12-00497-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d0/8870963/add5264c1945/diagnostics-12-00497-g008.jpg

相似文献

1
Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer.在转移性前列腺癌男性患者中分离和增殖循环肿瘤细胞的策略
Diagnostics (Basel). 2022 Feb 15;12(2):497. doi: 10.3390/diagnostics12020497.
2
isolation of circulating tumor cells in patients with different stages of prostate cancer.不同前列腺癌分期患者循环肿瘤细胞的分离
Oncol Lett. 2021 May;21(5):357. doi: 10.3892/ol.2021.12618. Epub 2021 Mar 4.
3
The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.使用新型细胞收集器从不同前列腺癌阶段患者的血液中分离循环肿瘤细胞及其临床结果——一项概念验证研究。
PLoS One. 2016 Aug 1;11(8):e0158354. doi: 10.1371/journal.pone.0158354. eCollection 2016.
4
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.单独使用抗细胞角蛋白或与抗上皮细胞粘附分子抗体联合使用进行富集,可显著提高转移性乳腺癌患者循环肿瘤细胞检测的灵敏度。
Breast Cancer Res. 2008;10(4):R69. doi: 10.1186/bcr2131. Epub 2008 Aug 7.
5
Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device.利用双抗体功能化微流控装置对前列腺癌患者的循环肿瘤细胞进行分子谱分析。
Anal Chem. 2018 Mar 20;90(6):3744-3751. doi: 10.1021/acs.analchem.7b03536. Epub 2018 Feb 28.
6
Analogous detection of circulating tumor cells using the AccuCyte -CyteFinder system and ISET system in patients with locally advanced and metastatic prostate cancer.在局部晚期和转移性前列腺癌患者中使用AccuCyte - CyteFinder系统和ISET系统对循环肿瘤细胞进行类似检测。
Prostate. 2018 Mar;78(4):300-307. doi: 10.1002/pros.23474. Epub 2017 Dec 29.
7
Comparison of circulating tumor cell (CTC) detection rates with epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) antibodies in different solid tumors: a retrospective study.不同实体瘤中上皮细胞粘附分子(EpCAM)和细胞表面波形蛋白(CSV)抗体检测循环肿瘤细胞(CTC)的比率比较:一项回顾性研究
PeerJ. 2021 Mar 2;9:e10777. doi: 10.7717/peerj.10777. eCollection 2021.
8
A FACS-based novel isolation technique identifies heterogeneous CTCs in oral squamous cell carcinoma.一种基于荧光激活细胞分选术的新型分离技术可识别口腔鳞状细胞癌中异质性循环肿瘤细胞。
Front Oncol. 2024 Feb 26;14:1269211. doi: 10.3389/fonc.2024.1269211. eCollection 2024.
9
Effective Circulating Tumor Cell Isolation Using Epithelial and Mesenchymal Markers in Prostate and Pancreatic Cancer Patients.利用上皮和间充质标志物有效分离前列腺癌和胰腺癌患者的循环肿瘤细胞
Cancers (Basel). 2023 May 18;15(10):2825. doi: 10.3390/cancers15102825.
10
Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.通过微滤捕获的循环肿瘤细胞的细胞计量学特征及其与CellSearch(®)循环肿瘤细胞检测的相关性。
Cytometry A. 2015 Feb;87(2):137-44. doi: 10.1002/cyto.a.22613. Epub 2014 Dec 16.

引用本文的文献

1
Detection of circulating tumor cells in non-metastatic prostate cancer through integration of a microfluidic CTC enrichment system and multiparametric flow cytometry.通过微流控 CTC 富集系统和多参数流式细胞术检测非转移性前列腺癌中的循环肿瘤细胞。
PLoS One. 2024 Oct 23;19(10):e0312296. doi: 10.1371/journal.pone.0312296. eCollection 2024.
2
Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.重新审视癌症检测与治疗的标准,并将其与现代方法进行比较。
World J Methodol. 2024 Jun 20;14(2):92982. doi: 10.5662/wjm.v14.i2.92982.
3
Dual targeting negative enrichment strategy for highly sensitive and purity detection of CTCs.

本文引用的文献

1
isolation of circulating tumor cells in patients with different stages of prostate cancer.不同前列腺癌分期患者循环肿瘤细胞的分离
Oncol Lett. 2021 May;21(5):357. doi: 10.3892/ol.2021.12618. Epub 2021 Mar 4.
2
Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment.循环肿瘤细胞在前列腺癌诊断和治疗中的临床应用研究进展。
Biomed Res Int. 2021 Jan 8;2021:6230826. doi: 10.1155/2021/6230826. eCollection 2021.
3
Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients.
用于循环肿瘤细胞高灵敏度和高纯度检测的双靶向负富集策略
Front Chem. 2024 May 20;12:1400988. doi: 10.3389/fchem.2024.1400988. eCollection 2024.
4
Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas.评估循环肿瘤细胞富集技术,以建立一种适用于胶质母细胞瘤临床应用的方法。
Front Neurol. 2024 Feb 28;15:1358531. doi: 10.3389/fneur.2024.1358531. eCollection 2024.
5
RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients.对从前列腺癌患者诊断性白细胞分离产物中系统性捕获的循环肿瘤细胞进行RNA分析。
Mater Today Bio. 2022 Nov 10;17:100474. doi: 10.1016/j.mtbio.2022.100474. eCollection 2022 Dec 15.
循环肿瘤细胞在前列腺癌和乳腺癌患者临床常规诊疗中的地位
Cancers (Basel). 2020 Dec 15;12(12):3782. doi: 10.3390/cancers12123782.
4
Genomic and phenotypic heterogeneity in prostate cancer.前列腺癌的基因组和表型异质性。
Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16.
5
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic.循环肿瘤细胞:从实验室到癌症临床
Cancers (Basel). 2020 Aug 21;12(9):2361. doi: 10.3390/cancers12092361.
6
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients.不同方法在转移性乳腺癌患者循环肿瘤细胞富集中的比较性能。
PLoS One. 2020 Aug 13;15(8):e0237308. doi: 10.1371/journal.pone.0237308. eCollection 2020.
7
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.具有致瘤和转移能力的循环乳腺癌细胞的特征。
EMBO Mol Med. 2020 Sep 7;12(9):e11908. doi: 10.15252/emmm.201911908. Epub 2020 Jul 15.
8
Deciphering cancer clues from blood.从血液中解读癌症线索。
Science. 2020 Mar 27;367(6485):1424-1425. doi: 10.1126/science.abb0736.
9
The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.基于大小的分离与无选择技术的联合应用为转移性前列腺癌患者提供了比单一方法更高的循环肿瘤细胞检测灵敏度。
BJU Int. 2020 Jul;126(1):191-201. doi: 10.1111/bju.15041. Epub 2020 Mar 29.
10
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.循环肿瘤细胞中的前列腺特异性膜抗原是去势抵抗性前列腺癌的新的预后不良标志物。
PLoS One. 2020 Jan 27;15(1):e0226219. doi: 10.1371/journal.pone.0226219. eCollection 2020.